Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**dexamethasone + salbutamol** is a combination therapy consisting of two drugs: dexamethasone, a synthetic corticosteroid, and salbutamol (also known as albuterol), a selective beta-2 adrenergic receptor agonist. Dexamethasone acts by suppressing inflammation and immune responses, stabilizing cell membranes, and reducing airway edema. Salbutamol relaxes bronchial smooth muscle through stimulation of beta-2 receptors, leading to bronchodilation and rapid relief of bronchospasm. This combination is primarily used in the treatment of acute wheezing, asthma exacerbations, and lower respiratory conditions in infants and children where both airway inflammation and bronchospasm are contributing factors. Evidence suggests that the combination may offer improved efficacy due to possible synergistic effects: corticosteroids may potentiate beta-2 receptor responsiveness, resulting in more rapid and marked clinical improvement in acute episodes compared to monotherapy with either agent[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + salbutamol.